Market Research Blog – Page 442 – New Product Development

Electric Cargo Bike Industry Poised to Exceed USD 18,052.7 million by 2034, Growing at an 14.2% CAGR, Reports FMI

Electric Cargo Bike Market — Electric Cargo Bike Industry

The global electric cargo bike industry size is anticipated to reach USD 4,781 million in 2024. It is predicted to grow at a CAGR of 14.2% during the forecast period to reach a value of USD 18,052.7 million by 2034.

This growth is largely driven by the surge in e-commerce, which has heightened the demand for efficient last-mile delivery solutions. Electric cargo bikes are ideally suited to address the challenges of urban areas, where congestion and limited parking space can impede the effectiveness of delivery vans and trucks. These bikes provide a faster, more cost-effective delivery option, making them increasingly attractive as e-commerce continues to expand.

The rising demand for electric cargo bikes is further fueled by significant investments from key industry players responding to the booming e-commerce sector. For instance, on November 24, 2022, Amazon announced plans to expand its electric cargo bike fleet in the United Kingdom. This initiative aims to improve delivery efficiency and contribute to the decarbonization of the transportation network used for package deliveries.

The growing e-commerce market, combined with the impact of the pandemic, has accelerated the need for home delivery services. Consequently, businesses are investing more in enhancing logistics and transportation to reduce downtime, cut costs, and boost customer satisfaction. This increased investment is expected to drive further demand for electric cargo bikes in the coming years.

Key Takeaways

The United States electric cargo bike market is expected to grow with a CAGR of 9.5% during the forecast period.
The demand for electric cargo bikes in Australia is expected to grow with a CAGR of 11.5% during the forecast period.
By battery type, the lithium-ion battery segment is projected to grow with an impressive CAGR of 12% during the forecast period.
The market in Germany is expected to grow with a significant CAGR of 11.6% throughout the forecast period.

“The thriving e-commerce industry and use of electric cargo bikes for fast parcel deliveries are expected to drive market growth during the forecast period,”– comments an FMI analyst.

Competitive Landscape

The market for electric cargo bike is highly competitive, with numerous prominent industry players making substantial investments in their production.

The key industry players are Jiangsu Xinri E-Vehicle Co. Ltd., Jinhua Jobo Technology Co., Ltd., CERO ELECTRIC CARGO BIKES, Worksman Cycles, DOUZE Factory SAS, XYZ CARGO, Butchers & Bicycles ApS, NIHOLA, Babboe, Yuba Electric Cargo Bikes, BODO Vehicle Group Co., Ltd. (LUXMEA), Chongqing Mobimax Technology Co., Ltd., Carqon (Accell Group N.V.), XCYC (Gemeinnützige Werkstätten und Wohnstätten GmbH ), Riese & Müller GmbH, Urban Arrow, Rad Power Bikes Inc., Tern Bicycles (Mobility Holdings, Ltd.), Pedego Electric Bikes, Xtracycle Inc, Amsterdam Bicycle Company, Triobike.

Some recent developments in the electric cargo bike industry are:

In October 2022, French company Douze Cycles introduced a series of cargo bikes comprising four models, three of which feature electric assistance. These bikes offer an impressive hauling capacity of up to 205 kg.
In June 2022, Tern unveiled NBD, a low-step e-bike capable of supporting a maximum gross vehicle weight of 140 kg. It features a rear rack with a capacity of up to 27 kg and a front rack that can handle up to 20 kg.
DOUZE Factory SAS, a French company specializing in cargo bike design and manufacturing, revealed a collaboration with Toyota on March 8, 2023. Together, they will co-develop and launch a new lineup of electric cargo bikes.
On November 3, 2022, Yuba Bikes from California introduced their popular non-motorized ‘longtail’ bicycles. These bikes have an extended deck for carrying cargo or passengers. Yuba expanded their cargo bike range with the new Fastrack model, featuring a patent-pending integrated Dual Rack System that can be adjusted in four ways to accommodate different cargo or passenger.

Key Segments Profiled in the Electric Cargo Bike Industry Survey

By Product Type:

Two Wheeled
Three Wheeled
Four Wheeled

By Battery Type:

Lead-Based
Nickel Based
Lithium Ion

By End-Use:

Courier & Parcel Service Provider
Large Retail Supplier
Personal Transportation
Service Delivery
Waste & Municipal Services

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer, Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Automotive Tuner Industry to Reach USD 12 Billion by 2033, Growing at a 6.4% CAGR, Reports FMI

Automotive Tuner Market — Automotive Tuner Industry

The global automotive tuner industry is projected to grow from USD 6.4 billion in 2023 to USD 12 billion by 2033, with a compound annual growth rate (CAGR) of 6.4% over the forecast period.

This expansion is driven by the rising popularity of aftermarket automotive modifications, particularly among young adults and Generation Y consumers, who are eager to personalize and customize their vehicles with aftermarket products.

The market growth is also supported by the increasing availability of aftermarket products. The globalization of the automotive industry has led to a greater number of companies offering diverse aftermarket products and services. This wider availability enhances consumer access to desired products and fosters healthy competition among suppliers.

Affordability is another key factor fueling market growth. As the global economy improves, more consumers have disposable income to spend on aftermarket products. Consequently, companies are able to offer products at lower price points, making them accessible to a broader audience.

The market is further buoyed by growing consumer preference for high-power engines and fuel-efficient vehicles, along with an increase in disposable income. Additionally, the expansion of aftermarket vehicle repair and service options contributes to market growth.

Advanced engine technologies, such as Electronic Control Units (ECUs), are expected to offer new growth opportunities for the market. Furthermore, the rising sales of high-end luxury vehicles and the increasing costs of OEM high-powered vehicles are also driving industry expansion.

Key Takeaways

United States automotive tuner market is expected to grow with a CAGR of 6.1% during the forecast period.
The market in China is expected to grow with a CAGR of 6.5% during the forecast period.
By component type, the hardware segment is projected to grow with a significant CAGR of 6.7% during the forecast period.
The market in India is expected to grow with a CAGR of 6.4% throughout the forecast period.

“The utilization of advanced engine technology and increasing affordability of aftermarket components is expected to drive market growth during the forecast period,” – comments an FMI Analyst

Competitive Landscape

The automotive tuner market is intensely competitive, with several key industry players investing heavily in providing these services.

The key industry players are Roo Systems, EFI Live, Magic Motorsports, Edge Products, Derive Systems, Cobb Tuning, Alientech SRL, Diablo Sport, Mountune, Autotuner, AEM Electronics, Hypertech Inc., HP Tuners, Flashtec SA, Jet Performance Products.

Key industry players are utilizing organic growth strategies like acquisitions, mergers, tie-ups, and collaboration to bolster their product portfolio. This is expected to propel the global automotive tuner market.

In April 2023, Mountune unveiled the launch of the mountune N1 engine series, a range of high-performance long-block crate engines particularly engineered for motorsport enthusiasts and professional race teams.
In April 2022, Motul, a well renowned oil & lubricants company, initiated a technical partnership with Mountune USA.
In May 2023, ABT Sportsline, a well-known tuner specializing in Audi and VW Group vehicles, unveiled the limited edition ABT RS6 Legacy Edition (LE).

Key Segments Profiled in the Automotive Tuner Industry Survey

Component Type:

Hardware Component
Software

By Vehicle Type:

Passenger Car
LCV
HCV

By Fuel Type:

Gasoline
Diesel

By Sales Channel:

Direct Sales
Third Party Online Channel
Independent Stores/Shops
Other Sales Channel

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Numerology Computation: A Comprehensive Overview

Have you ever been curious regarding the mystical world of numerology and exactly how it can assist you unlock your real possibility? In this extensive overview, we will look into the remarkable world of numerology calculation and how you can utilize it to obtain understandings into your life path, characteristic, and future possibilities.

What is Numerology?

Numerology is the belief in the magical and magnificent connection in between numbers and occasions in the physical world. It is based upon the idea that each number has its very own one-of-a-kind power and vibration that can influence our lives in profound ways. By studying the patterns and significances of numbers, we can gain a much deeper understanding of ourselves and the world around us.

Numerology has actually been utilized for centuries by cultures around the world, consisting of ancient human beings like the Egyptians, Greeks, and Chinese. It is an effective device for self-discovery and individual growth, helping us to discover our staminas, weak points, and concealed abilities.

At its core, numerology is based on the principle that every little thing in the universe is attached best psychic reading and that numbers are the building blocks of reality. By examining the numbers in our names and birthdates, we can unlock the tricks of our spirit’s objective and fate.

Life Course Number
Expression Number
Spirit Desire Number
Personality Number

Each of these numbers provides understanding into different elements of our character and life course, helping us to make better decisions and browse life’s obstacles with knowledge and clearness.

Exactly how to Determine Your Numerology Numbers

Determining your numerology numbers is a straightforward process that entails breaking down your name and birthdate into their numerical matchings. Each letter in the alphabet is assigned a number, from 1 to 9, and these numbers are utilized to calculate your various numerology numbers.

As an example, to determine your Life Course Number, you would certainly combine the numbers in your birthdate (day, month, and year) till you get to a single figure number. This number discloses your inherent talents, toughness, and challenges, in addition to the chances and barriers that may emerge in your life.

Similarly, your Expression Number is calculated by converting the letters in your full name into numbers and adding them together. This number shows your exterior personality and the way you reveal yourself to the world.

Once you have calculated your numerology numbers, you can start to discover their meanings and exactly how they affect various elements of your life. By recognizing the special powers of each number, you can gain important insights right into your relationships, occupation, health and wellness, and personal development.

The Power of Numerology

Numerology is an effective tool for self-discovery and personal development, offering us a deeper understanding of ourselves and the world around us. By studying the patterns and definitions of numbers, we can open the secrets of our heart’s objective and destiny, assisting us to make much better choices and live more authentically.

Whether you are new to numerology or have been studying it for several years, the method of numerology can supply extensive insights and guidance for navigating life’s difficulties and possibilities. By welcoming the knowledge of numbers, we can align ourselves with the universe’s natural rhythms and fulfill our true capacity.

In Conclusion

Numerology is a fascinating and effective device for self-discovery and individual growth, providing us understandings into our strengths, weak points, and covert skills. By calculating our numerology numbers and understanding their definitions, we can get valuable insights right into our life path, personality traits, and future opportunities.

Open the tricks of numerology and start a trip of self-discovery and personal development today!

Check out the magical world of numerology and discover the covert meanings of numbers that can transform your life in extensive ways. Welcome the power of numerology and unlock your true capacity!

Global Edward’s Syndrome Treatment Market to Reach USD 7.98 Billion by 2033, Driven by Advancements in Research and Diagnostic Technologies | FMI

The global edward’s syndrome treatment market is poised for significant growth, with a projected market value of USD 7.98 billion by 2033, up from USD 4.9 billion in 2023. This represents a compound annual growth rate (CAGR) of 5% during the forecast period from 2023 to 2033, according to new market insights.

Edward’s syndrome, or Trisomy 18, is a rare chromosomal disorder that occurs in approximately 1 in 5,000 live births. Characterized by severe intellectual disabilities and physical abnormalities, the condition often leads to high mortality rates in infants, with many not surviving beyond their first few months. However, advancements in medical technology are enabling earlier and more accurate diagnoses, driving a growing demand for treatment options.

The increasing prevalence of genetic testing is also contributing to this market growth. As more families are informed about the presence of the disorder, there is a rising need for effective treatment solutions. Moreover, ongoing investment in research and development is fostering innovation in therapies and interventions that aim to improve outcomes for affected individuals.

Over the historical period from 2018 to 2022, the Edward’s syndrome treatment market experienced a steady growth, registering a CAGR of 3%. However, with improvements in both diagnostics and treatment methodologies, the market is now positioned to accelerate its growth significantly.

Industry experts predict that with continued advancements in genetic testing, prenatal screening, and therapeutic development, the Edward’s syndrome treatment market will expand, bringing new hope to families and healthcare providers.

As the global healthcare landscape continues to evolve, stakeholders are urged to focus on research, education, and early diagnosis to address the rising demand for treatment and care for those affected by this challenging condition.

Key Takeaways:

Market Growth: The global Edwards syndrome treatment market is projected to reach USD 4.9 billion in 2023 and is expected to grow to USD 7.98 billion by 2033, registering a CAGR of 5% during the forecast period (2023–2033). The market saw a CAGR of 3% from 2018 to 2022.
Research & Development: The increase in investment in research and development is a key factor driving the growth of the Edwards syndrome treatment market.
North America Market Dynamics: North America is expected to capture a 45% market share in 2023. This growth is driven by the widespread availability of prenatal screening, which allows for early and accurate diagnosis of Edwards syndrome. Additionally, support organizations such as the Trisomy 18 Foundation play a key role in providing resources and advocacy for affected families.
Asia Pacific Market Outlook: Asia Pacific is anticipated to hold a 39% market share in 2023, fueled by increasing access to advanced healthcare resources, genetic screening techniques, and favorable government support in countries like China, India, and Japan.
End-User Insights: The hospital segment is expected to dominate the Edwards syndrome treatment market with a 40% market share in 2023. This is due to the availability of comprehensive treatments, diagnostics, and the presence of healthcare experts and cardiologists. Government initiatives and reimbursement schemes also support the growth of hospitals as the primary treatment setting for Edwards syndrome.

Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis!

Market Competition:

Key players in the Edwards syndrome treatment market include Merck & Co., Kyorin Pharmaceuticals, Pfizer Inc., Bellus Health, Eli Lilly and Company, GeneScience Pharmaceuticals Co., Ltd., Johnson & Johnson Private Limited, Teva Pharmaceutical Industries Ltd., Sanofi, and Bayer AG.

Sanofi, a prominent player in the Edwards syndrome treatment market, is focusing on leveraging technology to develop diagnostic tests aimed at improving treatment outcomes for Edwards syndrome.
Similarly, Johnson & Johnson Private Limited is prioritizing research and development investments to drive innovation in medications for Edwards syndrome.

Key Segments Profiled in the Edward’s Syndrome Treatment Industry Survey:

Types:

Full Trisomy 18
Mosaic Trisomy 18
Partial Trisomy 18

Treatment:

Cardiac Treatment
Assisted Feeding
Orthopaedic Treatment
Psychosocial Support
Others

End User:

Hospitals
Clinics
Ambulatory Surgical Centres
Others

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐅𝐌𝐈’𝐬 𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐎𝐧𝐠𝐨𝐢𝐧𝐠 𝐂𝐨𝐯𝐞𝐫𝐚𝐠𝐞 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐃𝐨𝐦𝐚𝐢𝐧:

Veterinary Vaccines Industry
India Static Compression Therapy Industry
Antibodies Industry

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Set for Remarkable Growth, Reaching USD 288.5 Million by 2033

The global eosinophilic granulomatosis with polyangiitis treatment market is on the cusp of significant expansion, according to recent market analysis. The market, which was valued at USD 173.8 million in 2023, is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.2%, reaching an impressive USD 288.5 million by 2033.

Several key factors are driving this upward trajectory. Advancements in healthcare technology have played a pivotal role, enabling more effective and targeted treatment options for patients suffering from EGPA, also known as Churg Strauss syndrome. This rare condition, characterized by inflammation of blood vessels, leads to restricted blood flow to various organs and tissues.

The increasing demand for EGPA treatment is fueled by heightened patient awareness and the availability of effective therapeutics. Developed economies, buoyed by government initiatives and improvements in healthcare infrastructure, and are expected to witness substantial market growth.

Moreover, the market benefits from the presence of numerous manufacturers with robust drug pipelines and substantial investments in research and innovation, further accelerating its promising trajectory.

“EGPA is a condition that demands effective treatment solutions, and the market is responding with innovative therapies and heightened accessibility,” stated FMI. “As we navigate demographic shifts and technological advancements, the market’s growth is poised to address the evolving needs of patients worldwide.”

Key Takeaways from the Market Study:

As of 2023, the eosinophilic granulomatosis with polyangiitis treatment market was valued at USD 173.8 Million
From 2023 to 2033, the eosinophilic granulomatosis with polyangiitis treatment industry is poised to grow at 5.2% CAGR
By 2033, the eosinophilic granulomatosis with polyangiitis treatment market is slated to reach a valuation of USD 288.5 Million
Based on the distribution channel, hospital pharmacy segment accounts for market share of 35.7% during the forecast period.
China is poised to yield a CAGR of 4.8% with respect eosinophilic granulomatosis with polyangiitis treatment in 2033.

Increased Market Attention: Delve into Detailed Trends and Analysis with Our Report!

Competitive Landscape:

Some of the key players present in the global eosinophilic granulomatosis with polyangiitis treatment markets are

Genentech Inc
F. Hoffmann-La Roche AG
Cephalon Inc.
Teva Pharmaceutical Industries Ltd.
Amgen Inc.
Sanofi S.A.
Koninklijke DSM N.V
AstraZeneca
Novartis International AG
GlaxoSmithKline LLC
Baxter Healthcare Corporation

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industries.

In April 2021 – Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
In December 2020 – Amgen announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA).

Key Segments Covered in Eosinophilic Granulomatosis with Polyangiitis Treatment Industry Survey:

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Drug Class:

Steroids
Immunosuppressant
Biologics
Immune Globulins

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Route of Administration:

Oral
Intravenous
Intramuscular

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Distribution Channel:

Hospital Pharmacies
Drug stores
Retail Pharmacies
Online Pharmacies

Eosinophilic Granulomatosis with Polyangiitis Treatment Market by Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)

Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:

Empty Capsules Industry
Urinary Tract Infection (UTI) Treatment Industry
Digital Breast Tomosynthesis (DBT) Equipment Industry

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Drug Eruptions Treatment Market to reach USD 7.1 billion by 2033, Antihistamines to account for 41% of all Treatments: FMI Study

The global drug eruptions market is estimated to be valued USD 3.89 billion in fiscal year 2023, compared to USD 3.66 billion in fiscal year 2022. The global market is anticipated to increase steadily from 2023 to 2033 at a 6.2% CAGR, reaching USD 7.1 billion by the end of that year. Skin sensitivity to a medication’s component causes a drug rash. The most prevalent drug-induced disorders are rashes. They have an impact on 5 to 15% of pharmaceutical regimens. Both prescription as well as the over-the-counter medication regimens are included in this. Both allergic and nonallergic drug reactions are possible.

Any medicine has the potential to result in a rash, although some are better known to do so. These include nonsteroidal anti-inflammatory medicines (NSAIDs), anti seizure medications, and antibiotics (particularly penicillins and sulfa pharmaceuticals). Such factors are propelling the revenues in the global market for drug eruptions from 2023 to 2033. The high expense associated with medication eruptions during the forecast period may be one of the main challenges facing the global market for these products. Increasing pharmacovigilance concurrently can aid in reducing adverse drug interactions and, as a consequence, prevent any possible eruptions brought on by different drugs. Therefore, these issues may limit the market’s expansion and thereby reduce demand for the management of drug eruptions.

North America is considered to be the most volatile market for the treatment of drug eruptions. According to a survey conducted in the United States in 2021, penicillin and related medications were responsible for 18% of drug eruption reports. Additionally, one in ten people developed an allergy to antibiotics that included sulfonamide. Therefore, there will be a lot of room for growth in this regional market for North American manufacturers throughout the projection period.

Key Takeaways from the Market Study

The market for drug eruptions expanded at a CAGR of 5.2% from 2018 to 2022.
The market for drug eruptions is expected to grow steadily from 2023 to 2033, at a 6.2% CAGR.
Antihistamines are predicted to command the market in 2023 with a 41% revenue share.
With a 21% market share in 2023, the intravenous method of administration segment will hold the second-largest segment during the projected period.
From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 7.3%.
The market for drug eruptions in Europe is anticipated to expand at a stable CAGR of 6.2%.

“The emergence of novel treatment modalities, growing awareness of various drug allergies, and a rise in demand in developing markets are the main factors driving the global market for drug eruptions during the forecast period.” comments a Future Market Insights analyst.

Accelerated Market Demand: Find Comprehensive Insights and Trends in Our Full Report!

Competitive Landscape:

Anuh Pharma Ltd.
Avik Pharma
Pfizer CentreOne
Hovione
Bausch Health Companies Inc.
APOTEX
Astellas Pharma, Inc.
Sanofi
Novartis AG
SBH Sciences

Some of the recent developments in this domain are:

In 2020, Sanofi India launched ‘Allergy Free’ initiative, a multi-channel educational campaign to promote awareness regarding allergies as well as their impact on one’s quality of life. Given the worldwide pandemic’s sensitivity, there is a lingering sense of panic that has captivated everyone. Allergy free educates individuals on the common symptoms of allergies, medication allergies, flu and cold symptoms, and the primary warning indications of COVID-19.

Key Segment:

By Drug Class:

Corticosteroids
Immunosuppressant Drugs
Anti-cytokines
Hemorrheologic Agents
Antihistamines

By Route of Administration:

Oral
Parenteral
Intravenous
Others

By Distribution Channel:

Hospital Pharmacies
Online Pharmacies
Others

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)

Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:

India Thyroid Function Test Industry
Fertility and Pregnancy Rapid Test Kit Industry
Wearable Medical Devices Industry

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Oncology-Based In-Vivo CRO Market Set for Explosive Growth, Projected to Reach USD 2.9 Billion by 2033 at a CAGR of 10.9%

The global oncology-based in-vivo CRO market is on the brink of remarkable expansion, driven by a growing demand for advanced cancer research and innovative treatment development. Recent market projections reveal that the sector, valued at USD 1.1 billion in 2023, is expected to reach an impressive USD 2.9 billion by 2033. This growth trajectory represents a robust Compound Annual Growth Rate (CAGR) of 10.9% over the next decade.

This significant market expansion reflects the critical need for intensified oncology research in the face of rising global cancer incidence rates. The oncology-based in-vivo CRO sector plays a pivotal role in advancing cancer treatment through comprehensive research services, encompassing preclinical and clinical trials. These efforts are essential to developing innovative and effective therapies to combat the growing cancer burden worldwide.

The market’s rapid growth is fueled by several key factors, including technological advancements, the rise of personalized medicine, and a stronger focus on targeted cancer treatments. As the global cancer burden continues to escalate, with 19.3 million new cases and 10 million fatalities reported by the World Health Organization (WHO) in 2020, the urgency for accelerated research has never been more pressing. The development of novel cancer therapies has become a global priority, driving the demand for in-vivo CRO services.

Pharmaceutical companies, recognizing the need to address this global health crisis, are increasingly outsourcing their oncology research activities to specialized CROs. This strategic shift allows companies to optimize resources while benefiting from the expertise, efficiency, and cost-effective solutions offered by CROs. In turn, this surge in outsourcing is propelling the market forward, positioning CROs as essential partners in the race to discover breakthrough cancer treatments.

The influx of research and development investment towards oncology-based in-vivo CROs underscores the sector’s critical role in addressing the global cancer challenge. As research activities continue to intensify, the oncology CRO market is poised for sustained growth and transformation throughout the forecast period.

Industry stakeholders are well-positioned to seize emerging opportunities, leveraging the latest advancements in cancer research and fostering collaborative innovation. With a steadfast commitment to driving progress in oncology treatment, the global oncology-based in-vivo CRO market is on track to experience unprecedented growth in the coming years, offering hope for more effective and targeted cancer therapies.

Key Takeaways from Oncology-based In-Vivo CRO Market:

North America holds the largest market share with cancer therapy being increasingly adopted all over the US.
Europe holds the second-largest market share with the UK expected to be the flag bearer.
The Asia-Pacific is expected to grow on the back of extensive research being conducted in this regard. For instance – Crown Bioscience, in October 2020, did expand its capacity of the Asia-Pacific by opening a new-fangled oncology-based research facility at Zhongshan (China).

Competitive Analysis:

Evotech SE, in November 2020, entered into partnership with Rappta Therapeutics for developing a petite molecule reactivating PP2A that does suppress response regarding multiple oncogenic signaling pathways holding the responsibility of cancer progression.
Evotec, in April 2021, entered into partnership with Kazia Therapeutics to develop and commercialize its oncology project ‘EVT801’. The company’s objective is that of conducting phase I trial under Kazia’s sponsorship.
Evotec SE, in April 2021, did invest in OxVax (an immune-oncology company that has its base in Oxford University’s research enabling creation of next gen cancer vaccines) with purpose of outperforming the methods that exist. The vaccine trains the body to target tumors and get away with them.
Crown Bioscience, in October 2021, did launch 3D ex Vivo Patient Tissue Platform that makes use of the patient’s tumor tissue extracted from surgical resections, biopsies, and ascites or samples of pleural effusion and processed for preserving tumor microenvironment.
Charles River Laboratories, in October 2021, got acquired by Jackson Laboratory (better known as Jackson Laboratory Japan). It does provide access to resources and animal models, so as to help researchers make scientific advancements as well as breakthrough in development of drugs.
Researchers in Jackson Laboratory, in July 2022, successfully demonstrated responses of patients with BRCA mutations, thereby coming up with resistance against platinum-based therapy other than BRCA1 promoter methylation. The team made use of PDX (patient-derived xenograft) mouse models, patient data, and engineered cancer cell lines. They also came up with an algorithm for ovarian cancer and TNBC that potentially responds to chemotherapy.
The Jackson Laboratory team, in May 2022, did deploy ML for capturing accurate insights regarding cancer patients and interpret the images of tumor quicker and all the more accurately, thereby providing probability of more focused treatment without requirement for extra testing.
eTheRNA Immunotherapies, in March 2022, came up with a novel LNP (Lipid Nanoparticle) formulation service for supporting discovery as well as early pre-clinical development of RNA-based vaccines and therapeutics.
Moderna, Inc., in October 2022, along with Merck, did report that the latter had started developing PCV (personalized cancer vaccine) called mRNA-4157/V940 as per existent Collaboration and License Agreement.

Discover the Rising Demand for Oncology-based In-vivo CRO: Dive into Our Full Report for Detailed Trends and Insights!

What does the Report say?

The research study is based on indication (blood cancer (syngeneic model, PDX (patient derived xenograft), and xenograft), solid tumors (syngeneic model, patient derived xenograft (PDX), and xenograft), and other indications (syngeneic model, PDX (patient derived xenograft), and xenograft)).
With growing incidences of oncology-based cases coupled with need of developing new drugs to treat cancer patients, the global oncology-based in-vivo CRO market is expected to go great guns in the forecast period.

Key Companies Profiled:

The Jackson Laboratory
EVOTEC
WuXi AppTec
Toxicon Inc.
Crown Bioscience
Taconic Biosciences
Eurofins Scientific
ICON Plc
Charles River Laboratory
Covance
Others

Key Segments Covered in Oncology-based in-vivo CRO Industry Survey:

By Indication:

Blood Cancer
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft
Solid Tumors
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft
Other Indications
- Syngeneic Model
- Patient Derived Xenograft (PDX)
- Xenograft

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)

Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:

Negative Pressure Wound Therapy Industry
India Coronary Stent Industry
Hemostat Industry

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Global Cytokine Release Syndrome Management Market Poised for Growth, Expected to Reach USD 44.6 Billion by 2033

The global cytokine release syndrome management market is on track for substantial growth, with an estimated value of USD 23.32 billion in 2023. The market is projected to expand at a compound annual growth rate (CAGR) of 6.7% from 2023 to 2033, reaching an anticipated USD 44.6 billion by 2033. This growth is primarily driven by the increasing prevalence of autoimmune diseases and cancers, both of which contribute to the rising incidence of CRS.

Cytokine Release Syndrome, a life-threatening condition often triggered by immunotherapies, requires prompt intervention. The treatment landscape has been revolutionized by new-generation drugs like tocilizumab, siltuximab, and anakinra, which target pro-inflammatory cytokines to reduce the severity of CRS. These therapies, coupled with aggressive supportive care, including fluid resuscitation, anti-emesis, and anti-diarrhea medications, are improving outcomes for patients and significantly mitigating CRS symptoms.

The future of CRS management looks promising, with ongoing studies aimed at uncovering the underlying mechanisms of CRS and exploring additional treatment options. Researchers and healthcare providers are optimistic that these studies will lead to even more effective interventions in the near future, further enhancing patient care and outcomes.

As the global CRS management market grows, it is expected to see an influx of innovative treatments and therapies, marking a transformative shift in the way the condition is approached and treated.

Key Takeaways from the Market Study:

Globally, the cytokine release syndrome management market is expected to reach USD 23.32 billion by 2023.
This market is estimated to reach USD 44.6 billion by 2033.
Hospitals for cytokine release syndrome management are expected to grow 32% market share between 2023 and 2033.
The market for Tumour Necrosis Factor-TNF is projected to grow by 2.9% from 2023 to 2033.
Cytokine release syndrome management in North America expanded with a market share of 17% during the forecast period.
According to forecasts, the arthritis therapeutics market accumulate a share of 19% over the next few years.

“Advances in immunotherapies, the approval of new drugs, and CAR T-cell therapies are expected to further accelerate the growth of the cytokine release syndrome management market.” comments a Future Market Insights analyst.

Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!

Competitive Landscape:

The development of innovative diagnostic techniques is becoming increasingly important for companies, which will probably lead to a number of firms expanding their product lines, acquiring other companies, or merging their companies in the near future, as many are likely to focus on developing new diagnostic techniques.

Kite announced that the Food and Drug Administration (FDA) has approved the addition of prophylactic corticosteroids to the prescribing information for Yescarta®. The label on Yescarta includes information to guide physicians in managing and possibly preventing side effects associated with chimeric antigen receptor (CAR) T-cell therapies. To maximize the chances of CAR T-cell therapy being beneficial to as many patients as possible, Kite has been working closely with physicians since Yescarta’s first approval in 2012. CAR T therapy research is also focused on expanding into new diseases and early treatment lines, while continuously enhancing the safety and efficacy of existing treatments.
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc., reported stable response rates among 6 patients with relapsed/refractory AL amyloidosis using NXC-201. Six relapsed/refractory AL amyloidosis patients treated with NXC-201 have shown 100% complete response. Using clinical cancer research, 100% complete responses were observed; 100% organ responses were observed; and at 5.2 months, the duration of response was still unknown, resulting in an average reduction of 65% (2,656 pg/mL) in NT-proBNP from baseline. There was no grade 4 Cytokine Release Syndrome. ICANS neurotoxicity was not observed; NYHA stage improved by 2 stages.

Key Companies Profiled:

Hoffmann-La Roche Ltd; GlaxoSmithKline Plc; Novartis AG; Sanofi S.A; Pfizer Inc.; Bayer AG; Biocon; AbbVie Inc.; Johnson & Johnson Private Limited; Incyte Corporation; Swedish Orphan Biovitrum; Genentech

Key Segments Profiled in the Cytokine Release Syndrome Management Industry Survey:

By Cytokine Type:

Tumor Necrosis Factor-TNF
Interleukins-II
Interferons-IFN
Epidermal Growth Factor-EGF

By Therapeutic Application:

Cancer
Asthma
Airway Inflammation
Arthritis
Others

By Biomarker Type:

Interleukin-10
Interferon Gamma
Interleukin-6
Ferritin
Cluster of Differentiation-163

By Route of Administration:

Oral
Intravenous

By End User:

Hospitals
Specialty Clinics
Others

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Explore FMI’s Related Ongoing Coverage on Healthcare Market Insights Domain:

Europe Viscosupplementation Industry
Arthroscopy Procedure and Products Industry
Electronic Medical Records (EMR) Industry

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Stretch Hood Film Market is Expected to Progress at a CAGR of 2.7% from 2024 to 2034 | FMI

The global stretch hood film market is poised for steady growth, with its size anticipated to reach USD 1,066.7 million by 2034, according to recent market projections. The market, currently valued at USD 820.4 million in 2024, is expected to register a modest but consistent compound annual growth rate (CAGR) of 2.7% over the next decade.

As e-commerce continues to grow rapidly, the dynamics of packaging are evolving, prompting companies to adapt to the unique challenges posed by online shopping. The demand for stretch hood films capable of accommodating the various sizes and shapes of items shipped through e-commerce channels is on the rise.

This surge in demand is driven by the need for packaging solutions that ensure product integrity during transit, streamline fulfillment processes, and enhance the overall customer experience. Companies that align their packaging strategies with the evolving requirements of the fast-growing e-commerce market are well-positioned to capitalize on the ongoing digital transformation in the retail sector.

Understand the Evolution: Request the Previous Source for This Report!

Moreover, there is a significant opportunity to innovate in the area of heavy-duty stretch hood films by incorporating features that promote reuse or resealability. As consumer awareness of environmental issues continues to grow, the demand for sustainable packaging solutions is becoming increasingly important. Stretch hood films that offer easy resealing for palletized cargo or encourage reuse can play a crucial role in supporting eco-friendly packaging practices.

Key Takeaways of Stretch Hood Films Market Study

The U.S. stretch hood film market is expected to grow at a 1.4% CAGR through 2034.
Germany’s stretch hood film market is projected to increase at a 1.0% CAGR through 2034.
India is anticipated to experience significant growth in stretch hood film demand, with an estimated CAGR of 5.6% through 2034.
Japan’s stretch hood film market is forecasted to rise at a 1.5% CAGR through 2034.
South Korea is expected to see a 1.9% CAGR in stretch hood film sales through 2034.
The rise of e-commerce is a major driving force behind the increased demand for stretch hood films that can handle various product sizes and shapes.

Competitive Landscape

The stretch hood film market is dynamic and competitive, with established global players, regional manufacturers, and newcomers. Coveris Holdings S.A., AEP Industries Inc., and Atlantis-Pak Co. Ltd. are among the market’s top rivals, thanks to their diverse product offerings, technological knowledge, and vast distribution networks.

These industry giants maintain a competitive advantage by consistently investing in R&D, offering innovative goods, and strategically expanding their global presence.

Key Players in the Stretch Hood Film Market

Muller Load Containment Solution
Trioplast Industrier AB
Sigma Stretch Film Corp.
Thrace Group
Malpack Corp.
Integrated Packaging Films
Malankara Plastics
Innovia Films
Malpack Corp.
FlexSol Packaging Corp.
RKW Group
Berry Global Inc.

Recent Developments

In February 2024, Charter Next Generation (CNG), a leading sustainable film creator, expanded its Titanium 5™ Stretch Hood film range to include Titanium 5P™ with 20% post-consumer recycled material. The new film has been road-tested and performs as well as or better than traditional film while also helping to achieve environmental goals.
In February 2023, Berry Global’s flexible films business introduced a next-generation version of its popular stretch hood film that contains at least 30% recycled plastic. This will enable firms to achieve their own sustainability goals while also satisfying the requirements of existing and future British and European plastics packaging laws.

Stretch Hood Film Market Segmentation

By Material:

Polyethylene
Ethylene Vinyl Acetate
Plastomers, Elastomers & Others

By Thickness:

Up to 50 microns
50 to 100 microns
100 to 150 microns
150 microns & above

By End Use:

Construction
Food & Beverages
Pharmaceuticals
Consumer Product
Paper Textile
Chemical & Fertilizers

By Region:

North America
Latin America
Western Europe
Eastern Europe
Asia Pacific (APAC)
Middle East & Africa (MEA)
Japan

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Metalized Barrier Film Market to be Worth USD 2.9 Billion by 2034: Future Market Insights, Inc.

The global metalized barrier films market, valued at USD 2.3 billion in 2024, is anticipated to reach USD 2.9 billion by 2034, growing at a steady CAGR of 2.7% over the forecast period, according to industry insights. The rise in globalization of the food and beverage industry and increasing health concerns among consumers are key factors driving this growth.

Metalized barrier films, which offer exceptional protection against environmental factors such as UV rays, moisture, and oxidation, are gaining traction across various end-use industries. The food & beverage, electronics, personal & home care, and pharmaceutical sectors are leading in the adoption of these films, especially in light of new regulations restricting the use of plastics. The rising consumer demand for ready-to-eat meals, driven by busy lifestyles, further fuels this growth.

See How Things Have Changed: Access the Old Source for This Report!

One of the significant benefits of metalized barrier films is their chemical inertness, ensuring no reactions with packaged food items. This property helps preserve the food’s original taste and flavor, making it an ideal packaging solution for maintaining product integrity.

Prominent Drivers of the Metalized Barrier Film Market

Growing Demand for Extended Shelf Life: Metalized barrier films provide excellent moisture, oxygen, and light barrier properties, significantly extending the shelf life of packaged food and beverages, which is driving their widespread adoption in the food packaging industry.
Rising Popularity of Flexible Packaging: The shift from rigid to flexible packaging due to its lightweight, cost-effectiveness, and sustainability advantages is boosting the demand for metalized barrier films, especially in consumer goods and pharmaceutical sectors.
Increased Focus on Sustainability: With growing environmental concerns, metalized barrier films are seen as a more sustainable alternative to traditional multi-layer plastic films, helping companies reduce their carbon footprint by using fewer materials.
Growth in E-Commerce and Retail Sectors: The boom in e-commerce, especially for food and personal care products, has created a higher demand for protective packaging, where metalized barrier films are crucial in ensuring product safety during transit.
Technological Advancements in Film Manufacturing: Innovations in metalized barrier film production, such as improved metallization processes and enhanced material properties, have led to better performance and cost efficiencies, further driving market growth.

Key Takeaways for Metalized Barrier Films Market:

The global market for metalized barrier films grew at a CAGR of 1.90% from 2019 to 2023.
China is expected to experience a CAGR of 5.1% in demand for metalized barrier films through 2034.
Thailand is projected to show a CAGR of 4.1% in the demand for these films from 2024 to 2034.
South Korea is estimated to witness a CAGR of 2.4% in the demand for metalized barrier films during 2024 to 2034.
The market for metalized barrier films in Spain is anticipated to grow at a CAGR of 2.1% through 2034.
India is projected to have the highest growth rate, with a CAGR of 6.5% through 2034.
The food and beverage sector is a major consumer of metalized barrier films and is expected to account for 61.4% of the market share in 2024.

Competitive Landscape

The metalized barrier film industry is highly competitive and has grown dramatically in recent years. Metalized barrier films are in high demand, particularly in emerging markets. To meet market demand and competition, manufacturers invest extensively in research and development, employ high-quality machinery, and build manufacturing facilities. Such techniques are expected to boost manufacturing capacities and keep ahead of the competition.

Key Companies in the Metalized Barrier Film Market

Uflex Ltd.
Polyplex Corporation Ltd.
DUNMORE Corporation Ltd.
Jindal Poly Films Ltd.
Bemis Company Inc.
Amcor Ltd.
Mondi Group plc
Henkel AG & Co. KGaA
SRF Limited
Forum Packaging
Cosmo Films Ltd.
Toray Plastics (America), Inc
Clifton Packaging Group

Recent Developments in the Metalized Barrier Film Market

In February 2024, UFlex showcased innovative products like Flexure SF’s “Nutri” series for food packaging, pharma, and hygiene applications. They also showcased barrier films like B-INM-M, C-CPM-ML-M, CPP metalized film, and C-CBP-WG CPP film.
In October 2023, Australian brand Madura Tea used Koehler NexPlus Seal Pure MOB 72 gsm flexible paper packaging. German suppliers Gundlach Packaging Group and Koehler Paper provided test materials after promising results.
In May 2023, UFlex introduced new products in Q4 FY23, including a metalized high-barrier tear polyester film for packaging applications, focusing on research-led innovation and sustainability.

Key Market Segmentation

By Material:

Plastic
- Polypropylene (PP)
- Polyethylene Terephthalate (PET)
- Polyamide (PA)
- Polyethylene (PE)
- Polyvinyl Chloride (PVC)
- Other Plastics
Metal
Aluminum
Copper

By Application:

Packaging
Decoration
Printing and Lamination
Labelling
Insulations

By End Use:

Food and Beverage
Pharmaceuticals
Cosmetics and Personal care
Automotive
Electricals and Electronics
Others

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube